Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
Control Bionics has been recognized by MedTech Outlook Magazine as the exclusive recipient of “Top 20 Medtech Companies – 2022,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the MedTech Outlook research and editorial team based on insights from an interview with Rob Wong, CEO.
Rob Wong, CEOWith the Control Bionics solution, users are able to communicate with friends and family, send and receive emails and text messages, browse the web, watch videos and movies, read the news, play games, control their home environmental control systems and more.![]()
Our entry into the assistive technology industry is based on our passion to serve those on the far end of the disability spectrum and the desire to drive the industry forward
Company
Control Bionics
Management
Rob Wong, CEO
Description
Control Bionics developed NeuroNode which is accessible, leading-edge assistive technology that can help those living with paralysis and loss of speech gain more control over their world. Control Bionics offers a suite of dedicated speech generating devices and AAC accessories to give people living with complex communication and physical needs their voice.
Sito Web:
mythras.it
Amministratore:
Roberto Livio Mastronardi, co-fondatore
Descrizione:
Mythras è un team di tecnici specializzati nell'assistenza tecnica su strumentazione IVD, esperti nell'aiutare i responsabili di laboratorio a garantire la precisione, l'accuratezza e la conformità dei loro strumenti. È la scelta ideale per numerosi clienti e distributori, al servizio delle loro complesse esigenze di assistenza tecnica e ricondizionamento della strumentazione IVD.
Citazione:
“Siamo certificati ISO 9001:2015 per l'assistenza tecnica e il ricondizionamento della strumentazione analitica IVD.”
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
